GlassScriptPhysician profile
Shivtaj S Mann
NPI 1871949883
$12,093.94
in general payments reported to CMS, 2019-2025
70 companies · $5,307 in 2025
The $5,307 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $194 · 2021: $99.95 · 2022: $723 · 2023: $2,534 · 2024: $2,788 · 2025: $5,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,462.89 |
| Education | $165.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,034.51 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $929.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $786.73 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Novartis Pharmaceuticals Corporation | $643.27 | 2022-2025 | |
| Daiichi Sankyo INC. | $607.23 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $510.35 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $497.97 | 2022-2025 | Opdivo, Opdualag |
| Incyte Corporation | $482.85 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $462.93 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $415.42 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $356.02 | 2023-2025 | Vonvendi, Fruzaqla, Ninlaro |
| Astrazeneca Pharmaceuticals LP | $322.75 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Genzyme Corporation | $300.17 | 2020-2025 | |
| Seagen INC. | $289.88 | 2019-2025 | Padcev, Tukysa |
| Eisai INC. | $222.61 | 2023-2025 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $213.48 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Beigene USA, INC. | $206.61 | 2023-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $191.58 | 2020-2025 | Libtayo, Lynozyfic |
| Beone Medicines USA, INC. | $186.88 | 2025 | Brukinsa, Tevimbra |
| Taiho Oncology, INC. | $170.25 | 2024-2025 | |
| Amgen INC. | $161.17 | 2023-2025 | Blincyto, Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $160.39 | 2019-2025 | |
| Genentech USA, INC. | $159.58 | 2022-2025 | Gavreto, Tecentriq, Alecensa |
| Sumitomo Pharma America, INC. | $146.09 | 2023-2025 | Orgovyx |
| Adc Therapeutics America, INC. | $143.59 | 2024-2025 | |
| Sobi, INC | $123.88 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $123.12 | 2019-2024 | Rezlidhia, Tavalisse |
| Tersera Therapeutics LLC | $113.09 | 2023-2025 | Zoladex, Quzyttir |
| Servier Pharmaceuticals LLC | $105.30 | 2023-2025 | |
| Gilead Sciences, INC. | $103.65 | 2022-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.61 | 2023-2025 | Gilotrif |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Adaptive Biotechnologies Corporation | $99.47 | 2022-2024 | Clonoseq |
| Exelixis INC. | $99.16 | 2023-2025 | Cabometyx |
| Amneal Pharmaceuticals LLC | $91.14 | 2024-2025 | Neulasta, Avastin, Neupogen |
| Array Biopharma INC | $88.17 | 2023-2024 | Braftovi, Mektovi, Lorbrena |
| Springworks Therapeutics, INC. | $79.85 | 2024-2025 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $79.11 | 2024-2025 | Provenge |
| Caris Mpi, INC. | $78.54 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $75.24 | 2023-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $73.58 | 2019-2025 | Orserdu |
| Acrotech Biopharma INC. | $62.93 | 2024-2025 | Beleodaq |
| Fennec Pharmaceuticals, INC. | $58.67 | 2024-2025 | Fyarro, Pedmark |
| Genentech, INC. | $53.45 | 2025 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $53.14 | 2023 | Imbruvica |
| Kite Pharma, INC. | $50.96 | 2023-2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $49.42 | 2023-2025 | Monoferric, Cosela |
| Myriad Genetic Laboratories, INC. | $47.77 | 2024-2025 | Myrisk, Precisetumor |
| Abbvie INC. | $46.28 | 2024-2025 | |
| Geron Corporation | $42.69 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $42.35 | 2024-2025 | Ultomiris |
| Cti Biopharma Corp. | $42.01 | 2023 | Vonjo |
| Janssen Scientific Affairs, LLC | $41.25 | 2025 | Carvykti, Talvey, Darzalex |
| Recordati_rare_diseases_inc. | $40.11 | 2025 | Enjaymo |
| Menarini Silicon Biosystems, INC. | $36.31 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $31.75 | 2019-2025 | Onivyde |
| Verastem, INC. | $26.50 | 2020 | |
| Spectrum Pharmaceuticals INC. | $25.63 | 2025 | Rolvedon |
| Genmab U.S., INC. | $24.17 | 2025 | Epkinly |
| Puma Biotechnology, INC. | $19.63 | 2022 | |
| Emd Serono, INC. | $19.58 | 2024 | |
| Foundation Medicine, INC. | $19.45 | 2023 | |
| Morphosys, US INC. | $18.19 | 2023 | Monjuvi |
| Kyowa Kirin, INC. | $17.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.04 | 2025 | |
| Immunocore Limited | $16.96 | 2025 | Kimmtrak |
| Aveo Pharmaceuticals, INC. | $16.65 | 2023 | Fotivda |
| Azurity Pharmaceuticals, INC. | $13.53 | 2025 | Vivimusta |
| Alnylam Pharmaceuticals INC. | $13.27 | 2023 | Onpattro |
| Iovance Biotherapeutics, INC. | $9.07 | 2024 | Amtagvi |
Drugs and devices associated with these payments
Keytruda $701Tecvayli $517Enhertu $464Opdivo $388Ojjaara $368Brukinsa $337Darzalex $333Jakafi $300Talvey $292Reblozyl $291Elrexfio $272Orgovyx $242Padcev $238Imbruvica $235Lenvima $223Kisqali $190Erleada $184Lynparza $177Xtandi $177Adcetris $174Inqovi $170Lonsurf $170Opdualag $167Tukysa $167Monjuvi $159Inlyta $151Blincyto $148Talzenna $143Scemblix $136Jaypirca $133Verzenio $130Vonjo $130Bosulif $129Fabhalta $126Imfinzi $124Pluvicto $124Nubeqa $121Pemazyre $119Avastin $111Tibsovo $105Vonvendi $104Fruzaqla $100Rezlidhia $99.94Tavalisse $99.94Cabometyx $99.16Ninlaro $98.37Polivy $90.51Calquence $88.68Braftovi $88.17Rybrevant $82.96Gilotrif $80.96Zoladex $80.01Provenge $79.11Mi Cancer Seek $78.54Datroway $75.93Pyrukynd $75.24Tasigna $74.91Mektovi $73.18Libtayo $72.16Ibrance $71.69Alecensa $69.97Tecentriq $69.97Rozlytrek $69.97Gavreto $69.97Enjaymo $68.22Zynlonta $68.02Vitrakvi $66.33Stivarga $66.33Lorbrena $65.37Venclexta $64.35Lynozyfic $63.38Tivdak $63.02Beleodaq $62.93Cablivi $57.07Tevimbra $56.96Orserdu $55.43Injectafer $51.11Sarclisa $50.97Ogsiveo $50.89Jemperli $50.67Zejula $50.67Vanflyta $50.37Fyarro $44.49Welireg $44.29Rytelo $42.69Ultomiris $42.35Trodelvy $41.85Neupogen $41.32Neulasta $41.32Carvykti $41.25Pomalyst $39.06Xospata $37.98Piqray $37.40Cellsearch $36.31Clonoseq $35.93Promacta $35.53Yescarta $34.04Hyqvia $33.51Quzyttir $33.08Monoferric $32.79
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivtaj Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.